DSpace Repository

Resistant Gram-negative infections in the outpatient setting in Latin America

Show simple item record

dc.contributor.author Salles, M.J.C.
dc.contributor.author Zurita, J.
dc.contributor.author Mejía, C.
dc.contributor.author Villegas, M.V.
dc.contributor.author Alvarez, C.
dc.contributor.author Bavestrello, L.
dc.contributor.author Berezin, E.
dc.contributor.author Gotuzzo Herencia, José Eduardo
dc.contributor.author Guzmán-Blanco, M.
dc.contributor.author Labarca, J.A.
dc.contributor.author Luna, C.M.
dc.contributor.author Nouer, S.
dc.contributor.author Rodríguez-Noriega, E.
dc.contributor.author Seas Ramos, Carlos Rafael
dc.date.accessioned 2022-01-04T20:29:57Z
dc.date.available 2022-01-04T20:29:57Z
dc.date.issued 2013
dc.identifier.uri https://hdl.handle.net/20.500.12866/10449
dc.description.abstract Latin America has a high rate of community-associated infections caused by multidrug-resistant Enterobacteriaceae relative to other world regions. A review of the literature over the last 10 years indicates that urinary tract infections (UTIs) by Escherichia coli, and intra-abdominal infections (IAIs) by E. coli and Klebsiella pneumoniae, were characterized by high rates of resistance to trimethoprim/sulfamethoxazole, quinolones, and second-generation cephalosporins, and by low levels of resistance to aminoglycosides, nitrofurantoin, and fosfomycin. In addition, preliminary data indicate an increase in IAIs by Enterobacteriaceae producing extended-spectrum β-lactamases, with reduced susceptibilities to third- and fourth-generation cephalosporins. Primary-care physicians in Latin America should recognize the public health threat associated with UTIs and IAIs by resistant Gram-negative bacteria. As the number of therapeutic options become limited, we recommend that antimicrobial prescribing be guided by infection severity, established patient risk factors for multidrug-resistant infections, acquaintance with local antimicrobial susceptibility data, and culture collection. en_US
dc.language.iso eng
dc.publisher Cambridge University Press
dc.relation.ispartofseries Epidemiology and Infection
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Latin America en_US
dc.subject drug safety en_US
dc.subject human en_US
dc.subject prescription en_US
dc.subject endemic disease en_US
dc.subject geographic distribution en_US
dc.subject risk factor en_US
dc.subject disease surveillance en_US
dc.subject disease association en_US
dc.subject systematic review en_US
dc.subject Drug resistance en_US
dc.subject bacterial strain en_US
dc.subject phenotype en_US
dc.subject South and Central America en_US
dc.subject genotype en_US
dc.subject bacterium detection en_US
dc.subject disease severity en_US
dc.subject drug effect en_US
dc.subject outpatient care en_US
dc.subject drug efficacy en_US
dc.subject treatment planning en_US
dc.subject bacterial virulence en_US
dc.subject antibiotic sensitivity en_US
dc.subject amikacin en_US
dc.subject clonal variation en_US
dc.subject bacterium isolate en_US
dc.subject Escherichia coli en_US
dc.subject ciprofloxacin en_US
dc.subject minimum inhibitory concentration en_US
dc.subject quinoline derived antiinfective agent en_US
dc.subject aminoglycoside en_US
dc.subject ceftriaxone en_US
dc.subject antibiotic resistance en_US
dc.subject cefepime en_US
dc.subject cefotaxime en_US
dc.subject ceftazidime en_US
dc.subject cephalosporin en_US
dc.subject cotrimoxazole en_US
dc.subject extended spectrum beta lactamase producing Enterobacteriaceae en_US
dc.subject Klebsiella pneumoniae en_US
dc.subject levofloxacin en_US
dc.subject piperacillin plus tazobactam en_US
dc.subject sultamicillin en_US
dc.subject ampicillin en_US
dc.subject meropenem en_US
dc.subject urinary tract infection en_US
dc.subject Salmonella en_US
dc.subject abdominal infection en_US
dc.subject amoxicillin plus clavulanic acid en_US
dc.subject cefoxitin en_US
dc.subject cephalosporin derivative en_US
dc.subject Citrobacter en_US
dc.subject concentration response en_US
dc.subject Enterobacter en_US
dc.subject ertapenem en_US
dc.subject Escherichia coli infection en_US
dc.subject extended spectrum beta lactamase producing Escherichia coli en_US
dc.subject fosfomycin en_US
dc.subject gentamicin en_US
dc.subject Gram negative infection en_US
dc.subject Gram-negative en_US
dc.subject imipenem en_US
dc.subject intra-abdominal infection en_US
dc.subject Klebsiella pneumoniae infection en_US
dc.subject nitrofurantoin en_US
dc.subject outpatient en_US
dc.subject Proteus en_US
dc.subject Serratia en_US
dc.title Resistant Gram-negative infections in the outpatient setting in Latin America en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1017/S095026881300191X
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.09
dc.relation.issn 1469-4409


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics